Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 7/2003

01-11-2003

Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): Co-expression in metastatic serous ovarian carcinoma

Authors: Ben Davidson, Vered Givant-Horwitz, Philip Lazarovici, Björn Risberg, Jahn M. Nesland, Claes G. Trope, Erik Schaefer, Reuven Reich

Published in: Clinical & Experimental Metastasis | Issue 7/2003

Login to get access
Metadata
Title
Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): Co-expression in metastatic serous ovarian carcinoma
Authors
Ben Davidson
Vered Givant-Horwitz
Philip Lazarovici
Björn Risberg
Jahn M. Nesland
Claes G. Trope
Erik Schaefer
Reuven Reich
Publication date
01-11-2003
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 7/2003
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/A:1027347932543

Other articles of this Issue 7/2003

Clinical & Experimental Metastasis 7/2003 Go to the issue

OriginalPaper

Real-time imaging of individual fluorescent-protein color-coded metastatic colonies in vivo

OriginalPaper

Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells

OriginalPaper

IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-α and DTIC

OriginalPaper

Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase

OriginalPaper

Inhibitory effect of antisense aminopeptidase N (APN/CD13) cDNA transfection on the invasive potential of osteosarcoma cells

OriginalPaper

Suppression of pancreatic cancer cell invasion by a cyclooxygenase-2-specific inhibitor
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits